Vector Science and Therapeutics (TSXV:PAIN) Cash Flow for Dividends: C$0.00 Mil (TTM As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:PAIN Vector Science and Therapeutics Corp TSXV:PAIN
14 GF Score
Price C$1.55
View Full Analysis

What is Vector Science and Therapeutics Cash Flow for Dividends?

Vector Science and Therapeutics TSXV:PAIN -4.32% 14 Cash Flow for Dividends is C$0.00 Mil as of Feb. 2026. GuruFocus rates TSXV:PAIN with a GF Score™ of 14/100.

Vector Science and Therapeutics's cash flow for dividends for the three months ended in Feb. 2026 was C$0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Feb. 2026 was C$0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Vector Science and Therapeutics Cash Flow for Dividends Related Terms

Vector Science and Therapeutics Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Vector Science and Therapeutics's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vector Science and Therapeutics Cash Flow for Dividends Chart

Vector Science and Therapeutics Annual Data
Trend Aug24 Aug25
Cash Flow for Dividends
0.00 0.00

Vector Science and Therapeutics Quarterly Data
Aug24 Nov24 Aug25 Nov25 Feb26
Cash Flow for Dividends 0.00 0.00 0.00 0.00 0.00
TSXV:PAIN
14GF Score
Vector Science and Therapeutics Corp TSXV:PAIN
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vector Science and Therapeutics Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of C$0.00 Mil mean?
Vector Science and Therapeutics (TSXV:PAIN) has a Cash Flow for Dividends of C$0.00 Mil as of Feb. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Vector Science and Therapeutics and its competitors.
Is Vector Science and Therapeutics' Cash Flow for Dividends too high?
Vector Science and Therapeutics' current Cash Flow for Dividends is C$0.00 Mil. Overall, Vector Science and Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Vector Science and Therapeutics' Cash Flow for Dividends compare to ABT and SYK?
Vector Science and Therapeutics' Cash Flow for Dividends of C$0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Medical Devices & Instruments company?
A good Cash Flow for Dividends depends on the Medical Devices & Instruments industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Vector Science and Therapeutics and its competitors. Vector Science and Therapeutics's current Cash Flow for Dividends is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vector Science and Therapeutics stock overvalued right now?
Vector Science and Therapeutics (TSXV:PAIN) has a current Cash Flow for Dividends of C$0.00 Mil. The current Cash Flow for Dividends is C$0.00 Mil. Vector Science and Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Vector Science and Therapeutics (TSXV:PAIN), the current Cash Flow for Dividends is C$0.00 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vector Science and Therapeutics Business Description

Vector Science and Therapeutics Corp develops novel biomechanical devices and active transdermal drug and peptide delivery platforms to equip clinicians with non-systemic, localized interventions targeting a broad cross-section of diseases and conditions where systemic delivery of interventions compromises the therapeutic effect or introduces unacceptable harm.
14GF Score

Get the complete analysis for TSXV:PAIN

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$1.55
Price